NRSN (NeuroSense Therapeutics) Cash Flow from Others: $-0.05 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NRSN NeuroSense Therapeutics Ltd NRSN
29 GF Score
Price $0.42
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics Cash Flow from Others?

NeuroSense Therapeutics NRSN -1.55% 29 Cash Flow from Others is $-0.05 Mil as of Dec. 2025. GuruFocus rates NRSN with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

NeuroSense Therapeutics's cash flow from others for the six months ended in Dec. 2025 was $-0.05 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.05 Mil.

NeuroSense Therapeutics Cash Flow from Others Related Terms

NeuroSense Therapeutics Cash Flow from Others Historical Data

* Premium members only.

The historical data trend for NeuroSense Therapeutics's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics Cash Flow from Others Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Others
Get a 7-Day Free Trial -1.93 0.04 -1.72 0.28 -0.05

NeuroSense Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.10 0.28 -0.01 -0.00 -0.05
NRSN
29GF Score
NeuroSense Therapeutics Ltd NRSN
Cash Flow from Others is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroSense Therapeutics Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.05 Mil.

Frequently Asked Questions Learn more about Cash Flow from Others →
What does a Cash Flow from Others of $-0.05 Mil mean?
NeuroSense Therapeutics (NRSN) has a Cash Flow from Others of $-0.05 Mil as of Dec. 2025. Cash Flow from Others is the amount of cash earned or paid from other, nonstandard operations. View historical data for NeuroSense Therapeutics and its competitors.
Is NeuroSense Therapeutics' Cash Flow from Others too high?
NeuroSense Therapeutics' current Cash Flow from Others is $-0.05 Mil. Overall, NeuroSense Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' Cash Flow from Others compare to PLUR and CALC?
NeuroSense Therapeutics' Cash Flow from Others of $-0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Others for a Biotechnology company?
A good Cash Flow from Others depends on the Biotechnology industry context. However, Cash Flow from Others should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Others mean?
A high Cash Flow from Others can signal that a stock is expensive relative to its fundamentals. Cash Flow from Others is the amount of cash earned or paid from other, nonstandard operations. View historical data for NeuroSense Therapeutics and its competitors. NeuroSense Therapeutics's current Cash Flow from Others is $-0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSN) has a current Cash Flow from Others of $-0.05 Mil. The current Cash Flow from Others is $-0.05 Mil. NeuroSense Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Others calculated?
Cash Flow from Others is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSN), the current Cash Flow from Others is $-0.05 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges H1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
29GF Score

Get the complete analysis for NRSN

Cash Flow from Others is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price